Oxandrin first won FDA approval in 1964. Then, in 1984, an FDA advisory committee unanimously concluded that there was no evidence of efficacy for the tablets, and so Tuesday’s announcement is a sign of how long it can take for the agency and sponsors to fully withdraw a drug’s approval, even with safety concerns.
Preview
Source: EndPoints
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.